PeptiMimesis secures €1.2M from Cap Innov’Est
News Apr 21, 2016
PeptiMimesis, a biopharma company dedicated to the discovery and development of therapeutic transmembrane peptides, announces the release of the €0.5m ($0.6m) first tranche of a €1.2m ($1.4m) investment made by Cap Innov’Est, a regionally-based seed fund.
The company will use this funding to initiate its research activities on the design and characterization of transmembrane peptides. PeptiMimesis aims to rapidly identify peptide candidates acting on validated targets in oncology, immuno-oncology and autoimmune diseases.
“PeptiMimesis is a very promising start-up company in the Cap Innov’Est portfolio,” said Jean-François Rax, investment director at Cap Innov’Est. "It has a highly experienced team, bringing together the academic founders, with great scientific knowledge in the field, and Domain Therapeutics’ preclinical research expertise and cutting-edge technology. It also signed a collaboration agreement with IPSEN, only 6 months after incorporation. This is the ideal configuration for rapid value creation.”
“We are very pleased to see Cap Innov’Est joining the company to leverage the potential of PeptiMimesis’ platform in the identification of first-in-class therapeutic peptides,” said Marjorie Sidhoum, president of PeptiMimesis. “We welcome follow-on investments to complete this series A and further accelerate the development of this innovative therapeutic strategy.”
Protein Target Identified That Could Prevent StrokesNews
Scientists have identified a protein, called GPR68, that senses blood flow and tells small blood vessels called arterioles when to dilate. The researchers believe medications that activate GPR68 could one day be useful to treat medical conditions, including ischemic stroke.READ MORE
Reversing an Unstoppable Cancer Cascade with ProteomicsNews
Mutations in genes that produce RAS proteins turn a normally benign process, essential for cellular growth, into a cancer stimulant that is currently undruggable. Now, cutting-edge protein analysis may help treat cancers caused by these mutations.READ MORE
The Protein and the PauparNews
Non-coding RNAs (ncRNA) exist in a limbo within cells, having been created from genes but never destined to be turned into functional protein. A ncRNA called Paupar has been shown to regulate a protein controlling brain growth, a first for these mysterious molecules.READ MORE